Concerns that changing methadone prescription laws will materially impact behavioral health providers are overblown, according to an analyst note from Jefferies Financial Group. The relaxed buprenorphine laws have not substantially increased prescriptions. Therefore, on the business side, the softened methadone prescription regulations would not cause providers such as Acadia Healthcare (Nasdaq: ACHC) to lose a significant portion of its opioid use disorder (OUD) treatment business, according to the note.
Read the full article: Concerns over Federal Methadone Legislation Overblown //
Source: https://bhbusiness.com/2024/04/03/concerns-over-federal-methadone-legislation-overblown-acadia-stock-remains-attractive